Yuxiao Wang & Parkway Clinical Laboratories Featured on Proactive Investors, Innovation in CBD & Designer Drug Testing
Parkway Clinical Laboratories Vice President of Lab Operations and Director of Research & Development Yuxiao Wang tells Proactive Investors the Pennsylvania-based lab is innovating in the CBD and designer-drug testing world, developing the “only CBD testing using urine and oral fluid samples.”
Wang says privately held Parkway aims to compete against lab giants like Laboratory Corporation of America Holdings (NYSE:LH) and Quest Diagnostics Inc (NYSE:DGX) by “spending extra time and effort” to developing its own specialized testing.
